COMMUNIQUÉS West-GlobeNewswire

Une plateforme néerlandaise rend les soins dermatologiques instantanément accessibles dans le monde entier
10/09/2025
Dermatology2Go se focalise sur les soins de la peau en ligne, sans temps d’attente et avec des informations fiables BERGEN OP ZOOM, Pays-Bas, 10 sept. 2025 (GLOBE NEWSWIRE) -- Une nouvelle plateforme néerlandaise a été [...]
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors
10/09/2025
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Realize Medical and Canon USA Partner to Redefine Procedural Planning Through Spatial Computing with VR and Imaging Technology
10/09/2025
Collaboration aims to create the lab of the future, enabling safer, faster, and more precise interventions Key Benefits of Partnership Integration of VR and imaging: Combines Realize Medical’s VR platform with Canon’s [...]
Johns Hopkins Health Plans Opens 2026 Grant Application Period
10/09/2025
Baltimore-Washington Region Nonprofits Invited to Apply for Grants Up to $20,000 HANOVER, Md., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Johns Hopkins Health Plans has launched the grant application period for its 2026 [...]
Partnership between Corewell Health and Nudj Health drives progress in chronic condition management
10/09/2025
The model is making lasting improvements to thousands of patients who have a broad spectrum of chronic conditions AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Corewell Health ™ patients who used virtual lifestyle [...]
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
10/09/2025
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™ , one of the largest digital health platforms for men, to make KYZATREX ® , an FDA- [...]
Tecan announces change of leadership in the Partnering Business division
10/09/2025
Männedorf, Switzerland, September 10, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering [...]
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
10/09/2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, delivering on its [...]
BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.
10/09/2025
Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol “STEX”. LOS ANGELES & VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ [...]
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
10/09/2025
WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will [...]
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer
10/09/2025
Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to validate the innovative [...]
IBA SA – NOTIFICATION TRANSPARENCE
10/09/2025
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), [...]
IBA – TRANSPARENCY NOTIFICATION
10/09/2025
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting
10/09/2025
PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Relmada Issues Mid-Year CEO Letter to Shareholders
10/09/2025
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related [...]
Three CorVel Partners Recognized as 2025 Theo Award Winners for Excellence in Workers’ Compensation
10/09/2025
Companies recognized for innovative approaches to biopsychosocial care, disaster response, and workplace safety FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Today, CorVel Corporation (NASDAQ: CRVL), a national [...]
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
10/09/2025
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
10/09/2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in patients with relapsing forms [...]
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
10/09/2025
Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. Cardiovascular [...]

Pages